Aleix Prat/clinicbarcelona.org
Apr 27, 2025, 08:55
Aleix Prat: ASCO 2025 annual meeting is coming!
Aleix Prat, Director of the Cancer Institute at the Hospital Clinic of Barcelona, posted on LinkedIn:
“American Society of Clinical Oncology (ASCO) 2025 annual meeting is coming!
Sessions are out!
We have 4 HER2DX studies with +800 patients with HER2+ breast cancer!
Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/CompassHER2 pCR trial.
15:12 GMT-5 Nadine M. Tung, MD, FASCO Abstract 501.HER2DX prognostic value in older patients with HER2-positive early breast cancer: A correlative analysis from the RESPECT phase III trial.
Kazuki Nozawa, MD Abstract 532 | Poster Bd 125HER2DX genomic test in HER2-positive breast cancer treated with 15 weeks of neoadjuvant paclitaxel, trastuzumab, and pertuzumab (THP): Final analysis from the BiOnHER clinical trial.
Bartomeu Fullana Grimalt, MD Abstract 607, Poster Bd 200 Bartomeu Fullana GrimaltQuantitative pre-treatment assessment of trastuzumab deruxtecan (T-DXd) antibody target (HER2) and payload target (topoisomerase 1, Topo1) to predict outcomes in metastatic breast cancer (MBC).”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 27, 2025, 08:55
Apr 27, 2025, 08:53
Apr 27, 2025, 08:49
Apr 27, 2025, 08:46
Apr 27, 2025, 08:26
Apr 27, 2025, 07:28